Achillion Analysts Weigh In; Maxim Downgrades, Highlights HCV Drug's Need for Extreme Levels of Safety
July 02, 2013 at 11:43 AM EDT
Shares of Achillion Pharma (NASDAQ: ACHN ) are down more than 24 percent Tuesday morning amid unfavorable FDA findings for its Hepatitis C drug Sovaprevir. A subsequent downgrade to Hold and removal of an $18 price target from Maxim is also weighing on shares this morning. "Disappointing" drug interactions between
